Comprehensive analyses of nuclear mitochondria‐related genes in the molecular features, immune infiltration, and drug sensitivity of clear cell renal cell carcinoma
Medicine Advances · 2024-09 · 2 (3) · 238-253
DOI: 10.1002/med4.72 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicine Advances, online erschienen am 04.09.2024. Verfasst von Yuchen Zhang und 9 weiteren Autor:innen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National College Students Innovation and Entrepreneurship Training Program.
Abstract (Originalsprache)
Background
Clear cell renal cell carcinoma (ccRCC) is one of the most common urological diseases and the most common subtype of renal cell carcinoma. Nuclear mitochondria‐related genes (MTRGs) play an essential role in cancer, but their effect on ccRCC has not been clarified. This work aimed to investigate the role of nuclear MTRGs in ccRCC.
Methods
We collected nuclear MTRGs from the MITOMAP database and obtained the ccRCC profile from the TCGA database. Gene expression validation came from the GEO database. The ccRCC subtypes were determined by unsupervised clustering analysis based on the nuclear MTRGs. Immune scores were computed using the EPIC algorithm. The drug sensitivity scores were calculated using GDSC resources. A nomogram explored the diagnostic value of the nuclear MTRGs.
Results
In total, 11 nuclear MTRGs were identified as both related to prognosis and differentially expressed in ccRCC, showing a significant positive correlation with CD274 expression. We determined two subtypes of ccRCC based on these genes and found remarkable differences in survival status, immune infiltration, mutation landscape, and drug sensitivity between the two subtypes. The high‐MTRG group had a better prognosis and a lower tumor stage than the low‐MTRG group. Immune checkpoint blockade therapy was more effective for the high‐MTRG group. A nomogram based on the nuclear MTRGs concluded that patients with a higher score had poorer survival. SUCLA2 (succinate‐CoA ligase ADP‐forming subunit beta) was identified as the hub gene linked to ccRCC. High SUCLA2 expression showed a correlation with better survival and a negative correlation with the tumor mutation burden in ccRCC. Pan‐cancer analysis revealed wide‐ranging roles for SUCLA2 across human tumors.
Conclusions
Nuclear MTRGs play vital roles in determining the molecular features, immune infiltration, and drug sensitivity of ccRCC. High levels of nuclear MTRGs may indicate a better prognosis for patients with ccRCC. SUCLA2 is a representative nuclear MTRG and may serve as a protective biomarker in ccRCC. Our study provides therapeutic guidance and potential biomarkers for ccRCC patients, and contributes to the advancement of precision medicine.
Förderung
- National College Students Innovation and Entrepreneurship Training Program
Zitieren
APA
Zhang, Y., Cao, H., Yang, F., Wang, X., Xu, Z., Cheng, M., Yang, S., Tian, X., Zhang, N., & Xie, Y. (2024). Comprehensive analyses of nuclear mitochondria‐related genes in the molecular features, immune infiltration, and drug sensitivity of clear cell renal cell carcinoma. Medicine Advances, 2(3), 238-253. https://doi.org/10.1002/med4.72
Vancouver
Zhang Y, Cao H, Yang F, Wang X, Xu Z, Cheng M, et al. Comprehensive analyses of nuclear mitochondria‐related genes in the molecular features, immune infiltration, and drug sensitivity of clear cell renal cell carcinoma. Medicine Advances. 2024;2(3):238-253. doi:10.1002/med4.72
BibTeX
@article{Zhang2024,
author = {Zhang, Yuchen and Cao, Huake and Yang, Feixiang and Wang, Xiaofeng and Xu, Zhihao and Cheng, Miao and Yang, Shuqi and Tian, Xuefeng and Zhang, Ning and Xie, Yinyin},
title = {Comprehensive analyses of nuclear mitochondria‐related genes in the molecular features, immune infiltration, and drug sensitivity of clear cell renal cell carcinoma},
journal = {Medicine Advances},
year = {2024},
volume = {2},
number = {3},
pages = {238--253},
doi = {10.1002/med4.72}
}
EUVIMED